Previous Article |
Table of Contents
| Next Article
Vol. 95, Issue 12, 6774-6778, June 9, 1998
* Departments of Molecular Biology and Chemistry, The Scripps
Research Institute, La Jolla, CA 92037; and Communicated by Michael G. Rossmann, Purdue University, West
Lafayette, IN, March 23, 1998 (received for review February 20, 1998)
A dynamic capsid is critical to the events that shape the viral
life cycle; events such as cell attachment, cell entry, and nucleic
acid release demand a highly mobile viral surface. Protein mass mapping
of the common cold virus, human rhinovirus 14 (HRV14), revealed both
viral structural dynamics and the inhibition of such dynamics with an
antiviral agent, WIN 52084. Viral capsid digestion fragments resulting
from proteolytic time-course experiments provided structural
information in good agreement with the HRV14 three-dimensional crystal
structure. As expected, initial digestion fragments included peptides
from the capsid protein VP1. This observation was expected because VP1
is the most external viral protein. Initial digestion fragments also
included peptides belonging to VP4, the most internal capsid protein.
The mass spectral results together with x-ray crystallography data
provide information consistent with a "breathing" model of the
viral capsid. Whereas the crystal structure of HRV14 shows VP4 to be
the most internal capsid protein, mass spectral results show VP4
fragments to be among the first digestion fragments observed. Taken
together this information demonstrates that VP4 is transiently exposed
to the viral surface via viral breathing. Comparative digests of HRV14
in the presence and absence of WIN 52084 revealed a dramatic inhibition
of digestion. These results indicate that the binding of the antiviral
agent not only causes local conformational changes in the drug binding pocket but actually stabilizes the entire viral capsid against enzymatic degradation. Viral capsid mass mapping provides a fast and
sensitive method for probing viral structural dynamics as well as
providing a means for investigating antiviral drug efficacy.
Human rhinovirus 14 (HRV14), the causative agent of the common
cold, is a member of a family of animal viruses MALDI-MS generates gas phase ions by the laser vaporization of a solid
matrix/analyte mixture in which the matrix (usually a small
crystalline organic compound) acts as a receptacle for energy
deposition. MALDI-MS typically provides picomole sensitivity and
accuracy on the order of 0.05% (i.e., ±0.5 Da on a 1,000-Da peptide).
The relatively low number of charge states generated with MALDI
(typically only the singly and doubly charged species are observed),
along with its high sensitivity and ability to simultaneously generate
ions from multicomponent mixtures, makes it especially well-suited for
analyzing viral proteins and peptides resulting from proteolytic
digests. In this study we demonstrate the use of MS to investigate the
solution structural dynamics of HRV14 and the efficacy of the antiviral
drug Win 52084.
HRV14 was prepared as previously described (6) to a final
concentration of 1 mg/ml in 10 mM TRIS buffer at pH 7.6. Trypsin digests were conducted at 25°C with 1 mg/ml virus in 25 mM
Tris·HCl, pH 7.7. The enzyme to virus ratio (wt/wt) was adjusted
to 1:100. Reaction volume was 10 µl, and 0.50 µl was removed from
the reaction at each time (5, 10, and 60 min), placed directly on the
MALDI analysis plate, and allowed to dry before the addition of matrix [0.5 µl of 3, 5-dimethoxy-4-hydroxy cinnamic acid (Aldrich) in a
saturated solution of acetonitrile/water (50:50) 0.25%
trifluoroacetic acid]. On-plate digestions (data not shown) were
performed at room temperature by using a mass spectrometer sample plate
derivatized with trypsin (Intrinsic Bioprobes, Tempe, AZ). MALDI-MS
mass analysis was conducted by using a Perceptive Biosystems
(Framingham, MA) Voyager Elite equipped with delayed extraction and a
nitrogen laser. External mass calibration typically was accurate to
0.05% and allowed unequivocal assignment of most proteolytic
fragments. The identity of trypsin released fragments was determined by
the Protein Analysis Worksheet (PAWS, MacIntosh version 6.0b2,
copyright 1995, Dr. Ronald Beavis) available on the Internet.
MALDI-MS mass analysis was conducted by using a Perceptive Biosystems
Voyager Elite and a Kratos Analytical Instruments MALDI-IV, both
equipped with delayed extraction and nitrogen lasers. All analyses were
conducted by using 0.5 µl of 3,5-dimethoxy-4-hydroxy cinnamic acid
(Aldrich) in a saturated solution of acetonitrile/water (50:50)
0.25% trifluoroacetic acid. External calibration typically was
accurate to 0.05% and allowed unequivocal assignment of most proteolytic fragments.
Previous proteolytic time-course experiments on the Flock house
virus (FHV) have clearly demonstrated (5), in combination with the
x-ray data, that portions of the capsid proteins are transiently
exposed on the viral surface. The time-course mass mapping of HRV14
performed in the present study revealed structural information in good
agreement with the three-dimensional crystal structure (2) and,
similarly to FHV, revealed results indicative of the transient exposure
of internalized capsid proteins. Trypsin digests contained fragments
resulting from the cleavage of residues residing near or included in
the neutralizing immunogenic (NIm) sites (NIm-IA, NIm-IB, NIm-II, and
NIm-III) (2) shown in Fig. 1
(Inset). Although the observation was expected, because NIm sites lie in loop regions on the exterior surface of the virus and are
therefore easily accessible to proteases, such cleavages are
significant evidence that mass mapping results are consistent with
viral structure. Likewise, initial digestion fragments (fragments produced in the first 5 min of digestion) included sequences from the
capsid protein VP1; this observation was expected because VP1 is
considered the most external viral protein (2).
Biophysics
Antiviral agent blocks breathing of the common cold virus
,
, and
Department of
Biological Sciences, Purdue University, West Lafayette, IN 49707
![]()
ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
References
the
picornaviruses
whose other members include the polio, hepatitis A, and
foot-and-mouth disease viruses (1). The HRV14 virion consists of an
icosahedral protein shell, or viral capsid, surrounding an RNA core.
The capsid is made up of 60 copies of each of four structural proteins,
VP1-VP4. Based on crystal structure data (2), VP1, VP2, and VP3
compose the viral surface, whereas VP4 lies interior at the
capsid/RNA interface. To examine the solution structure of HRV14, we
used protein mass mapping, limited proteolysis with mass spectrometry (3, 4). Here the site-specific proteolytic degradation of a protein
results in a set of digestion fragments which are subsequently mass
analyzed by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). The resulting digestion fragments provide structural information concerning the individual capsid proteins as
well as their protein-protein interactions, because available cleavage
sites are dependent on both the tertiary and quaternary protein
structure. For instance, cleavage sites residing on the exterior of the
virus will be most accessible to the enzyme and therefore be among the
first digestion fragments observed. Because proteolysis is performed in
solution and can detect different conformational species, this method
can contribute to an understanding of the dynamic domains within the
virus structure.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
References
![]()
RESULTS AND DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
References

View larger version (33K):
[in a new window]
Fig. 1.
Trypsin digestion time course of HRV14
(Inset). The asymmetric unit of HRV14 is shown such that
the interior RNA is located at the bottom of the diagram, the nearest
5-fold axis on the left, and the nearest 2-fold axis on the right. VP1,
VP2, VP3, and VP4 are blue, green, red, and mauve, respectively. Large
yellow balls denote initial cleavage sites after a 5-min incubation
with trypsin. Doubly charged species in the mass spectra are denoted by
2+. T = 0 represents undigested virus with VP4
observed at m/z= 7,390.0; VP1-VP3 (not
shown) are observed at m/z = 32,518.9 (VP1 expected 32, 519.5 Da), 28,475.9 (VP2 expected 28, 477.4 Da), and 26,219.5 (VP3 expected 26, 217.8 Da).
Also represented in the early stages of HRV14 digestions were fragments originating from VP4 (Fig. 1 and Table 1). This observation is particularly interesting in that VP4 is crystallographically defined as being internal to the larger capsid proteins (Fig. 1 Inset) and hence not expected to be readily accessible to proteolysis. When combined with the crystal structure data, the proteolysis results are consistent with a dynamic or "breathing" capsid in which the different capsid proteins fluctuate between different conformations and specific protein regions can translocate to the capsid surface (Fig. 2). A potential, although unlikely, explanation for the observation of digest fragments originating from VP4 is that a massive pore is exposed during the breathing process that allows trypsin to pass through. To test whether trypsin might enter the virion, digestions were performed with surface-bound enzymes. Whereas the digestion pattern changed when immobilized enzyme was used, buried residues and the NIm-IA site were still cleaved by the surface-bound enzyme. Therefore, a more likely explanation for the early observation of VP4 fragments can be derived from a thermodynamic model for HRV14 uncoating. In this model, HRV14 exists in at least two different structural states: one represented by the crystal structure where VP4 lies at the capsid/RNA interface, and the other, where VP4 protrudes from the viral interior and is accessible to proteases. Our results suggest that the energy barrier between these two states is relatively small because both are found at ambient temperatures. In addition, these results are similar to those from previous poliovirus studies, in which antibodies recognizing internal VP4 epitopes were found to bind when polio-virions were incubated with antibodies at physiological temperature (7). This was the first study to suggest that structural breathing (translocation of internal proteins to the exterior viral surface) may actually represent large dynamic changes in virion structure.
|
|
To determine the effects of drug binding on the viral capsid, enzymatic digestions were also performed in the presence of the antiviral agent WIN 52084. The x-ray crystal structure of HRV14 reveals a 25 Å deep canyon on the surface of the virion at each 5-fold axis of symmetry (8) that has been identified as the site of receptor attachment (9). WIN compounds bind to hydrophobic pockets in VP1, which lie beneath the canyon floor (10). Previous studies have shown that the binding of WIN compounds blocks cell attachment of some rhinovirus serotypes (11), inhibits the uncoating process, and stabilizes the viral capsid to thermal and acid inactivation (12-14). This stabilization occurs in spite of relatively minor changes in the capsid structure (10). In the presence of the drug, digestion by the free and immobilized enzyme (data not shown) was significantly retarded by WIN 52084 after exposure to the enzyme for 3 h (Fig. 3), and even after 18 h, only two digestion fragments were observed. Mass mapping of FHV in the presence of WIN 52084 revealed no inhibition of viral capsid degradation. Therefore, WIN inhibition of protease activity is clearly caused by specific effects on the availability of HRV14 cleavage sites and not on the protease itself (Fig. 4).
|
|
Our results, together with those of previous studies, suggest that drug
binding not only affects local conformation in the drug pocket and
canyon floor but has a global stabilizing effect on the entire viral
capsid. Studies of a number of antiviral drugs against poliovirus have
suggested that the drugs cause specific conformational changes in the
viral capsid proteins (15). The authors hypothesized that at ambient
temperatures the poliovirus samples a number of conformations and that
the different drug compounds "locked" the capsid in one of these
states. Our comparative digests suggest that this drug-induced
stability significantly retards enzymatic digestion because of loss of
flexibility in viral structure (breathing), which is required for
protease activity. Indeed, the antiviral agent not only blocks
digestion of internal residues but also protects the highly exposed
NIm-IA antigenic site that lies
25 Å away from the bound drug
(Figs. 1 and 3).
Furthermore, studies of naturally occurring HRV and polio mutants resistant to, and in some cases dependant on, WIN compounds show mutations not only in the drug-binding pocket but also distal to this site (16, 17). Our results substantiate the proposal that these distal mutations may impart drug resistance by decreasing the stability of the particles to compensate for WIN stabilization (16, 17). Finally, it has been shown that, whereas ICAM-1 (the cellular receptor recognized by the major group of rhinoviruses) binding to the southern portion of the canyon wall (9) destabilizes HRV14 (18), antibodies recognizing the NIm-IA site cause a stabilization effect. Antibodies recognizing other antigenic sites did not exhibit such stabilization effects (19). Because it is the NIm-IA site that is particularly sensitive to proteolytic cleavage in the absence of antiviral agents, results presented here suggest that antibody-mediated stabilization of virions may be caused by inhibition of conformational changes (breathing) around the NIm-IA site. The fact that the Fab portion (Fab17-IA) of a neutralizing antibody was observed to bind in the presence of small hydrophobic compounds bound to the drug cavity (20) suggests that Fab17-IA is recognizing and stabilizing the structure represented by the atomic model. As proposed for poliovirus (7, 15, 21), these results suggest that the canyon is a dynamic "trigger" region where a small amount of energy can result in large effects, either inducing or preventing uncoating. It is possible that WIN inhibits cellular attachment via this stabilization process rather than WIN-induced conformational changes, because not all of the major group rhinoviruses are affected to the same extent (22).
Interestingly, in our initial studies of HRV14 we observed the mass of VP4 to be 212 Da larger than predicted by the sequence (obtained from the Swiss-Prot Sequence Data Bank). Speculation as to the posttranslational modification of HRV14 structural proteins exists because of the observation of electron density, corresponding to the myristoylation of VP4 (23), in crystallographic data from HRV14. The 212-Da mass difference is consistent with VP4 myristoylation. Our results from further digestion and tandem MS structural studies of purified VP4 have localized myristoylation to the N terminus.
In conclusion, the observation of a highly dynamic capsid structure could fundamentally alter the way we look at viruses. Such observations, however, are not surprising given the events that shape the viral life cycle (1), a life cycle that demands a highly mobile viral surface. The use of MS (24) in combination with enzymatic probes (3-5) offers a unique means of examining dynamic events and also provides a complementary approach to the inherently static methods of crystallography and electron microscopy. The present results are consistent with those of previous studies (5, 7), which have also detected viral capsid mobility. Observation of drug-induced stability clearly demonstrates the conformational restraint that the WIN drug provides. In addition and equally important, is the potential use of this method as a rapid and sensitive mass-based assay for studying antiviral-drug activity.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Elaine Chase for the virus preparation and Jennifer Boydston for editorial comments. MolView (25) (http://bilbo.bio.purdue.edu/~tom) was used to prepare Figs. 1-3. This work was supported by National Institutes of Health Grants GM55775 (to G.S.) and GM10704 (to T.J.S.).
| |
FOOTNOTES |
|---|
To whom reprint requests should be addressed. e-mail:
tom{at}bragg.bio.purdue.edu and siuzdak{at}scripps.edu.
| |
ABBREVIATIONS |
|---|
HRV14, human rhinovirus 14; MALDI, matrix-assisted laser desorption/ionization; FHV, Flock house virus; NIm, neutralizing immunogenic.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Rueckert, R. R. (1996) Picornaviridae and Their Replication (Raven, New York), pp. 609-654. |
| 2. | Rossmann, M. G., Smith, T. J. & Rueckert, R. R. (1993) Structure Introductory Issue, xxiv-xxv. |
| 3. | Cohen, S. L., Ferre-D'Amare, A. R., Burley, S. K. & Chait, B. T. (1995) Protein Sci. 4, 1088-1099 [Abstract]. |
| 4. | Kriwacki, R. W., Wu, J., Siuzdak, G. & Wright, P. E. (1996) J. Am. Chem. Soc. 118, 5320-5321 [CrossRef]. |
| 5. |
Bothner, B., Dong, X.-F., Bibbs, L., Johnson, J. E. & Siuzdak, G.
(1998)
J. Biol. Chem.
273,
673-676
|
| 6. |
Erickson, J. W., Frankenberger, E. A., Rossmann, M. G., Fout, G. S., Medappa, K. C. & Rueckert, R. R.
(1983)
Proc. Natl. Acad. Sci. USA
80,
931-934
|
| 7. |
Li, Q., Yafal, A. G., Lee, Y. M. H., Hogle, J. & Chow, M.
(1994)
J. Virol.
68,
3965-3970
|
| 8. | Rossmann, M. G., Arnold, E., Erickson, J. W., Frankenberger, E. A., Griffith, J. P., Hecht, H. J., Johnson, J. E., Kamer, G., Luo, M., Mosser, A. G., et al. (1985) Nature (London) 317, 145-153 [CrossRef][Medline] . |
| 9. |
Olson, N. H., Kolatkar, P. R., Oliveira, M. A., Cheng, R. H., Greve, J. M., McClelland, A., Baker, T. S. & Rossmann, M. G.
(1993)
Proc. Natl. Acad. Sci. USA
90,
507-511
|
| 10. |
Smith, T. J., Kremer, M. J., Luo, M., Vriend, G., Arnold, E., Kamer, G., Rossmann, M. G., McKinlay, M. A., Diana, G. O. & Otto, M. J.
(1986)
Science
233,
1286-1293
|
| 11. |
Pevear, D. C., Fancher, M. J., Felock, P. J., Rossmann, M. G., Miller, M. S., Diana, G., Tresurywala, A. M., McKinlay, M. A. & Dutko, F. J.
(1989)
J. Virol.
63,
2002-2007
|
| 12. |
Rombaut, B., Andries, K. & Boeye, A.
(1991)
J. Gen. Virol.
72,
2153-2157
|
| 13. |
Fox, M. P., Otto, M. J. & McKinlay, M. A.
(1986)
Antimicrob. Agents Chemother.
30,
110-116
|
| 14. |
Gruenberger, M., Pevear, D., Diana, G. D., Kuechler, E. & And, O.
(1991)
J. Gen. Virol.
72,
431-433
|
| 15. | Hiremath, C. N., Filman, D. J., Grant, R. A. & Hogle, J. M. (1997) Acta. Crystallogr. D53, 558-570 . |
| 16. |
Mosser, A. G., Sgro, J. Y. & Rueckert, R. R.
(1994)
J. Virol.
68,
8193-8201
|
| 17. |
Mosser, A. G. & Rueckert, R. R.
(1993)
J. Virol.
67,
1246-1254
|
| 18. |
Hoover-Litty, H. & Greve, J. M.
(1993)
J. Virol
67,
390-397
|
| 19. | Lee, W. M. (1992) Dissertation (University of Wisconsin, Madison). |
| 20. | Smith, T. J., Chase, E. S., Schmidt, T. J., Olson, N. H. & Baker, T. S. (1996) Nature (London) 383, 350-354 [CrossRef][Medline] . |
| 21. | Chow, M., Basavappa, R. & Hogle, J. (1997) in Structural Biology of Viruses, eds. Chiu, W., Burnett, R. M. & Garcea, R. L. (Oxford, New York), pp. 157-186. |
| 22. | Pevear, D. C., Diana, G. D. & McKinlay, M. A. (1992) Semin. Virol. 2, 41-55 . |
| 23. | Arnold, E. & Rossmann, M. G. (1990) J. Mol. Biol. 211, 763-801 [CrossRef][ISI][Medline] . |
| 24. | Siuzdak, G. (1996) Mass Spectrometry for Biotechnology (Academic, San Diego, CA). |
| 25. | Smith, T. J. (1995) J. Mol. Graphics 13, 122-125 [CrossRef][Medline] . |
This article has been cited by other articles in HighWire Press-hosted journals:
![]() |
U. Katpally and T. J. Smith Pocket Factors Are Unlikely To Play a Major Role in the Life Cycle of Human Rhinovirus J. Virol., June 15, 2007; 81(12): 6307 - 6315. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Speir, B. Bothner, C. Qu, D. A. Willits, M. J. Young, and J. E. Johnson Enhanced local symmetry interactions globally stabilize a mutant virus capsid that maintains infectivity and capsid dynamics. J. Virol., April 1, 2006; 80(7): 3582 - 3591. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Stray, C. R. Bourne, S. Punna, W. G. Lewis, M. G. Finn, and A. Zlotnick A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly PNAS, June 7, 2005; 102(23): 8138 - 8143. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Wang and D. L. Smith Capsid structure and dynamics of a human rhinovirus probed by hydrogen exchange mass spectrometry Protein Sci., June 1, 2005; 14(6): 1661 - 1672. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li, Z. Zhou, and C. B. Post From the Cover: Dissociation of an antiviral compound from the internal pocket of human rhinovirus 14 capsid PNAS, May 24, 2005; 102(21): 7529 - 7534. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Xiao, T. J. Tuthill, C. M. Bator Kelly, L. J. Challinor, P. R. Chipman, R. A. Killington, D. J. Rowlands, A. Craig, and M. G. Rossmann Discrimination among Rhinovirus Serotypes for a Variant ICAM-1 Receptor Molecule J. Virol., September 15, 2004; 78(18): 10034 - 10044. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. K. Lee, J. Tang, D. Taylor, B. Bothner, and J. E. Johnson Small Compounds Targeted to Subunit Interfaces Arrest Maturation in a Nonenveloped, Icosahedral Animal Virus J. Virol., July 1, 2004; 78(13): 7208 - 7216. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Rice, L. Tang, K. Stedman, F. Roberto, J. Spuhler, E. Gillitzer, J. E. Johnson, T. Douglas, and M. Young From The Cover: The structure of a thermophilic archaeal virus shows a double-stranded DNA viral capsid type that spans all domains of life PNAS, May 18, 2004; 101(20): 7716 - 7720. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. H. Choi, J. M. Groarke, D. C. Young, R. J. Kuhn, J. L. Smith, D. C. Pevear, and M. G. Rossmann The structure of the RNA-dependent RNA polymerase from bovine viral diarrhea virus establishes the role of GTP in de novo initiation PNAS, March 30, 2004; 101(13): 4425 - 4430. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Hewat and D. Blaas Cryoelectron Microscopy Analysis of the Structural Changes Associated with Human Rhinovirus Type 14 Uncoating J. Virol., March 15, 2004; 78(6): 2935 - 2942. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Verdaguer, M. A. Jimenez-Clavero, I. Fita, and V. Ley Structure of Swine Vesicular Disease Virus: Mapping of Changes Occurring during Adaptation of Human Coxsackie B5 Virus To Infect Swine J. Virol., September 15, 2003; 77(18): 9780 - 9789. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Xing, J. M. Casasnovas, and R. H. Cheng Structural Analysis of Human Rhinovirus Complexed with ICAM-1 Reveals the Dynamics of Receptor-Mediated Virus Uncoating J. Virol., June 1, 2003; 77(11): 6101 - 6107. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-M. Lee and W. Wang Human Rhinovirus Type 16: Mutant V1210A Requires Capsid-Binding Drug for Assembly of Pentamers To Form Virions during Morphogenesis J. Virol., June 1, 2003; 77(11): 6235 - 6244. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Singh and A. Zlotnick Observed Hysteresis of Virus Capsid Disassembly Is Implicit in Kinetic Models of Assembly J. Biol. Chem., May 9, 2003; 278(20): 18249 - 18255. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. E. Fry, N. J. Knowles, J. W. I. Newman, G. Wilsden, Z. Rao, A. M. Q. King, and D. I. Stuart Crystal Structure of Swine Vesicular Disease Virus and Implications for Host Adaptation J. Virol., May 1, 2003; 77(9): 5475 - 5486. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. He, S. Mueller, P. R. Chipman, C. M. Bator, X. Peng, V. D. Bowman, S. Mukhopadhyay, E. Wimmer, R. J. Kuhn, and M. G. Rossmann Complexes of Poliovirus Serotypes with Their Common Cellular Receptor, CD155 J. Virol., April 15, 2003; 77(8): 4827 - 4835. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Vihinen-Ranta, D. Wang, W. S. Weichert, and C. R. Parrish The VP1 N-Terminal Sequence of Canine Parvovirus Affects Nuclear Transport of Capsids and Efficient Cell Infection J. Virol., February 15, 2002; 76(4): 1884 - 1891. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Suzuki, M. Yanai, M. Yamaya, T. Satoh-Nakagawa, K. Sekizawa, S. Ishida, and H. Sasaki Erythromycin and Common Cold in COPD Chest, September 1, 2001; 120(3): 730 - 733. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Tsang, B. M. McDermott, V. R. Racaniello, and J. M. Hogle Kinetic Analysis of the Effect of Poliovirus Receptor on Viral Uncoating: the Receptor as a Catalyst J. Virol., June 1, 2001; 75(11): 4984 - 4989. [Abstract] [Full Text] |
||||
![]() |
L. Wang, L. C. Lane, and D. L. Smith Detecting structural changes in viral capsids by hydrogen exchange and mass spectrometry Protein Sci., June 1, 2001; 10(6): 1234 - 1243. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. J. C. Snell New treatments for viral respiratory tract infections--opportunities and problems J. Antimicrob. Chemother., March 1, 2001; 47(3): 251 - 259. [Full Text] [PDF] |
||||
![]() |
K. Broo, J. Wei, D. Marshall, F. Brown, T. J. Smith, J. E. Johnson, A. Schneemann, and G. Siuzdak Viral capsid mobility: A dynamic conduit for inactivation PNAS, February 8, 2001; (2001) 51598298. [Abstract] [Full Text] |
||||
![]() |
M. A. Jiménez-Clavero, E. Escribano-Romero, A. J. Douglas, and V. Ley The N-Terminal Region of the VP1 Protein of Swine Vesicular Disease Virus Contains a Neutralization Site That Arises upon Cell Attachment and Is Involved in Viral Entry J. Virol., January 15, 2001; 75(2): 1044 - 1047. [Abstract] [Full Text] |
||||
![]() |
B. S. Phinney, K. Blackburn, and D. T. Brown The Surface Conformation of Sindbis Virus Glycoproteins E1 and E2 at Neutral and Low pH, as Determined by Mass Spectrometry-Based Mapping J. Virol., June 15, 2000; 74(12): 5667 - 5678. [Abstract] [Full Text] |
||||
![]() |
A. W. Dove and V. R. Racaniello An Antiviral Compound That Blocks Structural Transitions of Poliovirus Prevents Receptor Binding at Low Temperatures J. Virol., April 15, 2000; 74(8): 3929 - 3931. [Abstract] [Full Text] |
||||
![]() |
D. M. Belnap, D. J. Filman, B. L. Trus, N. Cheng, F. P. Booy, J. F. Conway, S. Curry, C. N. Hiremath, S. K. Tsang, A. C. Steven, et al. Molecular Tectonic Model of Virus Structural Transitions: the Putative Cell Entry States of Poliovirus J. Virol., February 1, 2000; 74(3): 1342 - 1354. [Abstract] [Full Text] |
||||
![]() |
Y. He, V. D. Bowman, S. Mueller, C. M. Bator, J. Bella, X. Peng, T. S. Baker, E. Wimmer, R. J. Kuhn, and M. G. Rossmann From the Cover: Interaction of the poliovirus receptor with poliovirus PNAS, January 4, 2000; 97(1): 79 - 84. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Pevear, T. M. Tull, M. E. Seipel, and J. M. Groarke Activity of Pleconaril against Enteroviruses Antimicrob. Agents Chemother., September 1, 1999; 43(9): 2109 - 2115. [Abstract] [Full Text] |
||||
![]() |
M. Arita, H. Horie, M. Arita, and A. Nomoto Interaction of Poliovirus with Its Receptor Affords a High Level of Infectivity to the Virion in Poliovirus Infections Mediated by the Fc Receptor J. Virol., February 1, 1999; 73(2): 1066 - 1074. [Abstract] [Full Text] |
||||
![]() |
B. O. Carragher, N. Cheng, Z.-Y. Wang, E. D. Korn, A. Reilein, D. M. Belnap, J. A. Hammer III, and A. C. Steven Structural invariance of constitutively active and inactive mutants of Acanthamoeba myosin IC bound to F-actin in the rigor and ADP-bound states PNAS, December 22, 1998; 95(26): 15206 - 15211. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Lewis, M. Bendahmane, T. J. Smith, R. N. Beachy, and G. Siuzdak Identification of viral mutants by mass spectrometry PNAS, July 21, 1998; 95(15): 8596 - 8601. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. M. McDermott Jr., A. H. Rux, R. J. Eisenberg, G. H. Cohen, and V. R. Racaniello Two Distinct Binding Affinities of Poliovirus for Its Cellular Receptor J. Biol. Chem., July 21, 2000; 275(30): 23089 - 23096. [Abstract] [Full Text] [PDF] |
||||
![]() |
|